• Je něco špatně v tomto záznamu ?

Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial

CV. Pollack, F. Davoudi, DB. Diercks, RC. Becker, SK. James, ST. Lim, PJ. Schulte, J. Spinar, PG. Steg, RF. Storey, A. Himmelmann, L. Wallentin, CP. Cannon, . ,

. 2017 ; 40 (6) : 390-398. [pub] 20170609

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024956

BACKGROUND: Guidelines suggest that "upstream" P2Y12 receptor antagonists should be considered in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS). HYPOTHESIS: Early use of ticagrelor in patients managed with an invasive strategy would be more effective than clopidogrel because of its more rapid onset of action and greater potency. METHODS: In the PLATO trial, 6792 NSTE-ACS patients were randomized to ticagrelor or clopidogrel (started prior to angiography) and underwent angiography within 72 hours of randomization. We compared efficacy and safety outcomes of ticagrelor vs clopidogrel as a function of "early" (<3h) vs "late" (≥3h) time to angiography. Adjusted Cox proportional hazards models evaluated interaction between randomized treatment and time from randomization to angiography on subsequent outcomes. RESULTS: Overall, a benefit of ticagrelor vs clopidogrel for cardiovascular death/myocardial infarction/stroke was seen at day 7 (hazard ratio [HR]: 0.67, P = 0.002), day 30 (HR: 0.81, P = 0.042), and 1 year (HR: 0.80, P = 0.0045). There were no significant interactions in the <3h vs ≥3h groups at any timepoint. For major bleeding, overall there was no significant increase (HR: 1.04, 95% confidence interval: 0.85-1.27); but there was a significant interaction with no difference between ticagrelor and clopidogrel in the early group (HR: 0.79), but higher bleeding risk with ticagrelor in the late angiography group, at 7 days (HR: 1.51, Pint = 0.002). Patterns were similar at 30 days and 1 year. CONCLUSIONS: The benefit of ticagrelor over clopidogrel was consistent in those undergoing early and late angiography, supporting upstream use of ticagrelor.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024956
003      
CZ-PrNML
005      
20180712100631.0
007      
ta
008      
180709s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/clc.22733 $2 doi
035    __
$a (PubMed)28598510
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Pollack, Charles V $u Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania.
245    10
$a Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial / $c CV. Pollack, F. Davoudi, DB. Diercks, RC. Becker, SK. James, ST. Lim, PJ. Schulte, J. Spinar, PG. Steg, RF. Storey, A. Himmelmann, L. Wallentin, CP. Cannon, . ,
520    9_
$a BACKGROUND: Guidelines suggest that "upstream" P2Y12 receptor antagonists should be considered in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS). HYPOTHESIS: Early use of ticagrelor in patients managed with an invasive strategy would be more effective than clopidogrel because of its more rapid onset of action and greater potency. METHODS: In the PLATO trial, 6792 NSTE-ACS patients were randomized to ticagrelor or clopidogrel (started prior to angiography) and underwent angiography within 72 hours of randomization. We compared efficacy and safety outcomes of ticagrelor vs clopidogrel as a function of "early" (<3h) vs "late" (≥3h) time to angiography. Adjusted Cox proportional hazards models evaluated interaction between randomized treatment and time from randomization to angiography on subsequent outcomes. RESULTS: Overall, a benefit of ticagrelor vs clopidogrel for cardiovascular death/myocardial infarction/stroke was seen at day 7 (hazard ratio [HR]: 0.67, P = 0.002), day 30 (HR: 0.81, P = 0.042), and 1 year (HR: 0.80, P = 0.0045). There were no significant interactions in the <3h vs ≥3h groups at any timepoint. For major bleeding, overall there was no significant increase (HR: 1.04, 95% confidence interval: 0.85-1.27); but there was a significant interaction with no difference between ticagrelor and clopidogrel in the early group (HR: 0.79), but higher bleeding risk with ticagrelor in the late angiography group, at 7 days (HR: 1.51, Pint = 0.002). Patterns were similar at 30 days and 1 year. CONCLUSIONS: The benefit of ticagrelor over clopidogrel was consistent in those undergoing early and late angiography, supporting upstream use of ticagrelor.
650    _2
$a akutní koronární syndrom $x diagnóza $x patofyziologie $x terapie $7 D054058
650    _2
$a adenosin $x aplikace a dávkování $x analogy a deriváty $7 D000241
650    _2
$a senioři $7 D000368
650    _2
$a koronární angiografie $7 D017023
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a elektrokardiografie $x účinky léků $7 D004562
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a revaskularizace myokardu $7 D009204
650    _2
$a inhibitory agregace trombocytů $x aplikace a dávkování $7 D010975
650    _2
$a antagonisté purinergních receptorů P2Y $x aplikace a dávkování $7 D058921
650    _2
$a tiklopidin $x aplikace a dávkování $x analogy a deriváty $7 D013988
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Davoudi, Farideh $u Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
700    1_
$a Diercks, Deborah B $u Department of Emergency Medicine, University of Texas Southwestern, Dallas.
700    1_
$a Becker, Richard C $u Division of Cardiovascular Health and Disease, Heart, Lung and Vascular Institute, University of Cincinnati College of Medicine, Ohio.
700    1_
$a James, Stefan K $u Department of Medical Sciences, Cardiology, and Uppsala Clinical Research Center, Uppsala University, Sweden.
700    1_
$a Lim, Soo Teik $u Department of Cardiology, National Heart Centre, Singapore.
700    1_
$a Schulte, Phillip J $u Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota; former employee at Duke Clinical Research Institute, Duke University Medical Center, North Carolina.
700    1_
$a Spinar, Jindrich $u Department of Internal Medicine/Cardiology, Masaryk University, Brno, Czech Republic.
700    1_
$a Steg, Philippe Gabriel $u Département Hospitalo-Universitaire FIRE, AP-HP, Hôpital Bichat, Paris, France; Paris Diderot University, Sorbonne Paris Cité, Paris, France; NHLI Imperial College, ICMS, Royal Brompton Hospital, London, UK; FACT (French Alliance for Cardiovascular Trials), an F-CRIN network, INSERM U1148, Paris, France.
700    1_
$a Storey, Robert F $u Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, United Kingdom.
700    1_
$a Himmelmann, Anders $u AstraZeneca Research and Development, Gothenburg, Sweden.
700    1_
$a Wallentin, Lars $u Department of Medical Sciences, Cardiology, and Uppsala Clinical Research Center, Uppsala University, Sweden. Department of Medical Sciences, Cardiology, Uppsala University, Sweden.
700    1_
$a Cannon, Christopher P $u Baim Institute for Clinical Research, and Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.
700    1_
$a ,
773    0_
$w MED00001122 $t Clinical cardiology $x 1932-8737 $g Roč. 40, č. 6 (2017), s. 390-398
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28598510 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180712100924 $b ABA008
999    __
$a ok $b bmc $g 1317087 $s 1021877
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 40 $c 6 $d 390-398 $e 20170609 $i 1932-8737 $m Clinical cardiology $n Clin Cardiol $x MED00001122
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Možnosti archivace